# NIH grant: Research on End-user Acceptability.and Long-term Impacts of HIV Cure Strategies (REALISE) (1R01AI201123-01) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/eb2e6694e7a1a6f4

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-06-18 00:00 ingested 2026-06-28 12:46

[original source ↗](https://reporter.nih.gov/project-details/1R01AI201123-01)

## retained text



```
NIH grant 1R01AI201123-01: Research on End-user Acceptability.and Long-term Impacts of HIV Cure Strategies (REALISE)
Institute: {'code': 'AI', 'abbreviation': 'NIAID', 'name': 'National Institute of Allergy and Infectious Diseases', 'admin_org_id': '12500003', 'admin_funding_url': ''}. PI: Elvin H. Geng. Award: $777756.
Start: 2026-06-18T00:00:00.
ABSTRACT
Despite remarkable advances in HIV cure science, emerging cure candidates will likely involve trade-offs (e.g.,
incomplete eradication, monitoring burdens) and must compete with increasingly convenient long-acting ART;
without early implementation guidance, even efficacious products may see limited uptake, particularly among
the ~30–40% of people with HIV (PWH) in the U.S. who are not durably suppressed.
We propose REALISE, a multidisciplinary program to define plausible cure profiles, quantify end-user
preferences, and project population-level impact to inform product design and policy before market entry.
Aim 1 conducts qualitative interviews with ~30 researchers and developers to delineate credible 10–20-year cure
and long-acting treatment scenarios (eradication vs functional control, safety, monitoring, durability), yielding
bounded “target product profiles.”
Aim 2 elicits patient-centered preferences through a two-stage study: formative interviews (n=60; ≥50% not virally
suppressed) to identify salient attributes; best-worst scaling (n=360 across Missouri, Georgia, and San
Francisco) to prioritize attributes; and a discrete choice experiment (n=360) to quantify trade-offs versus
alternative therapies, with latent class analysis to identify preference segments and estimate potential reach.
Aim 3 integrates preference-based uptake from Aim 2 with Aim 1 efficacy and cost inputs in a mathematical
model to estimate health impact, QALYs, net QALYs, and incremental cost-effectiveness across heterogeneous
populations and Ending the HIV Epidemic jurisdictions. Innovation lies in linking cure R&D horizons to end-user
preferences and transmission-dynamic outcomes, an approach that anticipates real-world use rather than
retrofitting after approval.
Deliverables include ranked cure attributes for product optimization, uptake projections including among
unsuppressed PWH, and jurisdiction-specific value assessments to guide public health investment.
By aligning cure design with what patients will accept and systems can sustain, REALISE will accelerate effective
deployment of future cure strategies and maximize their contribution to Ending the HIV Epidemic. In doing so,
this study advances NIH's priorities by connecting implementation science with prevention, treatment, and cure
research. Using a multidisciplinary strategy to refine and extend `target product profiles,' REALISE will ensure
cure development reflects patient needs and accelerate translation into real-world benefit.
```



document fetched 2026-06-28 13:47